300. IgG4-related disease Clinical trials / Disease details
Clinical trials : 40 / Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05625581 (ClinicalTrials.gov) | November 10, 2022 | 10/11/2022 | Tofatib Treatment for IgG4-related Disease | Clinical Study on the Efficacy and Safety of Tofatib and Cyclophosphamide in the Treatment of Active IgG4 Related Diseases | IgG4-related Disease | Drug: tofacitinib | Changhai Hospital | NULL | Recruiting | 18 Years | 75 Years | All | 40 | China |